Recently, the FDA announced that it will accept the listing application of the Xaar gene and Agios' variant IDH2 inhibitor enasidenib (formerly known as AG-221). The PDUFA date is August 30 this year. Enasidenib's application for indication is IDH2 variant relapsed, refractory AML. 15% of AML patients have IDH2 variants, and Abbott’s IDH2 variant kit also submits applications. In a phase I/II clinical trial involving 209 participants, enasidenib produced a 37% response rate, of which 18% responded completely. If approved, this will be the first anticancer drug for tumor metabolism. Drug source analysis Tumor metabolism is now a major therapeutic cancer research direction in parallel with immunotherapy. Since tumor cells are different from normal cell lifestyles, energy intake and utilization are also different from normal cells. IDH2 (isocitrate dehydrogenase) is an enzyme of energy metabolism that catalyzes the conversion of isocitrate to ketoglutarate (alpha-KG). This variant IDH2, which is common in AML, not only does not have this normal catalytic function, but also acquires a new catalytic function that catalyzes the conversion of ketoglutarate to hydroxyglutaric acid (2-HG). 2-HG is similar in structure to alpha-KG, so it inhibits many alpha-KG functions. The most important is to affect some epigenetic oxidases, causing abnormal gene expression and causing cancer. AML is a poorly controlled one in common hematological tumors. It is difficult to obtain an effect similar to ALL with an existing drug combination, and the recurrence rate is high. The development of new drugs has been slow, and the approved and under-researched drugs are less than ALL, so enasidenib is granted priority approval. A few new AML drugs listed in recent years include arsenic found by Chinese scientists for a rare AML called APL (<10%). Last year, the Israeli company BioLineRx's CXCR4 receptor inverse agonist BL8040 also produced a 38% response rate similar to enasidenib in a r/rAML phase II clinical trial. AML is highly heterogeneous, so it needs to be segmented. For example, today's enasidenib is used for IDH2 variants. The previous year's vacant Flt3 inhibitor PKC412 (midostaurin) was used in the Flt3 variant population, which was 23% less risk of death than placebo. CAR-T against AML is also being studied, but the lack of specific surface antigens is significantly slower than the progression of ALL CAR-T. Although precision medicine can increase the curative effect, it also divides the already small market more fragmented. This may be one of the reasons why manufacturers are not motivated. Innovative jet embedded nylon technology maximizes the efficiency of sample collection from patients. Nylon adheres vertically and evenly to the surface of the swab tip, improving the efficiency of cell and liquid sample collection and release. Increased analytical sensitivity, no specimen residue, and accelerated specimen processing. Flocked Swab,Collect swabs from specimens with flocked tips,Medical sampling swab oral nylon swab flocking,Acts in the clinical diagnosis Jiangsu iiLO Biotechnology Co., Ltd. , https://www.sjiilogene.com